Found 463 results in Expert Content

Summary: Integrated approach from development to clinical and benefits of working with a single integrated provider.

Summary: The transition from early phase to late phase of a small molecule program plays a pivotal role in determining a program’s ultimate success. Early planning strategies can help minimize the burdens often faced in that transition. The implementation of modeling tools...

This article discusses how quality by design (QbD) can be built into inhalation product development to ensure a drug and device are safe and effective.

Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.

The development of orally administered small molecules is more challenging as an many have poor aqueous solubility and bioavailability.

This article discusses why roller compaction is a robust option when developing a tablet or capsule formulation.

Summary: Characterize lead molecules and develop the best pathway to bring them to Phase I studies and beyond.

Summary: Thousands of drug candidates are abandoned annually due to solubility and bioavailability issues, but advanced formulation technologies can profoundly impact how a drug compound...

This webinar focuses on the key considerations for transitioning small molecules from preclinical through clinical development.

Summary: Recorded at Manufacturing Chemist Live 2020, this presentation discusses some of the key issues to consider when planning for the scale-up of a small molecule development program.